New RA drug KT502 enters first human safety trial
NCT ID NCT07564154
First seen May 05, 2026 · Last updated May 05, 2026
Summary
This early-stage study tests a new drug, KT502, in 27 adults with moderate to severe rheumatoid arthritis (RA) who have not responded well to other treatments. The main goal is to check safety and how the body handles the drug, not to cure the disease. Participants will receive injections of KT502, and researchers will monitor side effects and drug levels in the blood.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RHEUMATOID ARTHRITIS (RA) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Kali Therapeutics Trial Site
Bayswater, Victoria, Australia
-
Kali Therapeutics Trial Site
Auckland, NZ, New Zealand
Conditions
Explore the condition pages connected to this study.